SuperworthIDEXX Laboratories profit margin IDXX
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- 25.0%
- Operating margin, 12 months
- 32.0%
- Net margin on a year earlier
- +0.6 pts
- Peer median
- 12.6%
Over the twelve months to Jun 30, 2026, IDEXX Laboratories kept 25.0% of its revenue as net profit, with an operating margin of 32.0% and a gross margin of 62.4%.
Five years earlier its net margin was 23.9%.
The median for 10 diagnostics and research stocks of a similar size is 12.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 24.6% | 31.6% | 61.8% |
| FY2024 | 22.8% | 29.0% | 61.0% |
| FY2023 | 23.1% | 30.0% | 59.8% |
| FY2022 | 20.2% | 26.7% | 59.5% |
| FY2021 | 23.2% | 29.0% | 58.8% |
| FY2020 | 21.5% | 25.7% | 58.0% |
| FY2019 | 17.8% | 23.0% | 56.7% |
| FY2018 | 17.0% | 22.2% | 56.1% |
| FY2017 | 13.4% | 21.0% | 55.7% |
| FY2016 | 12.5% | 19.7% | 54.9% |
| FY2015 | 12.0% | 18.7% | 55.6% |
| FY2014 | 12.2% | 17.5% | 54.9% |
| FY2013 | 13.6% | 19.4% | 54.9% |
| FY2012 | 13.8% | 20.3% | 54.1% |
| FY2011 | 13.3% | 19.4% | 53.0% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 25.0% | +0.6 pts | 32.0% | |
| Q1 FY26 | 24.6% | +1.9 pts | 31.6% | |
| Q4 FY25 | 24.6% | +1.8 pts | 31.6% | |
| Q3 FY25 | 24.7% | +2.1 pts | 31.3% | |
| Q2 FY25 | 24.4% | +2.1 pts | 31.1% | |
| Q1 FY25 | 22.8% | −0.5 pts | 29.1% | |
| Q4 FY24 | 22.8% | −0.3 pts | 29.0% | |
| Q3 FY24 | 22.5% | −0.4 pts | 28.9% | |
| Q2 FY24 | 22.3% | −0.2 pts | 28.6% | |
| Q1 FY24 | 23.3% | +2.9 pts | 30.0% | |
| Q4 FY23 | 23.1% | +2.9 pts | 30.0% | |
| Q3 FY23 | 22.9% | +2.9 pts | 30.1% |
Against its peers
Companies in Medical - Diagnostics & Research nearest IDEXX Laboratories' size, closest first, today.
| Company | Profit margin |
|---|---|
| IDXXIDEXX Laboratories | 25.0% |
| WATWaters | 3.6% |
| IQVIQVIA | 8.1% |
| ILMNIllumina | 18.4% |
| AAgilent Technologies | 19.5% |
| MTDMettler-Toledo International | 21.9% |
| DGXQuest Diagnostics | 9.2% |
| LHLabcorp | 7.0% |
| MEDPMedpace | 17.7% |
| RVTYRevvity | 8.2% |
| DHRDanaher | 15.9% |
| Peer median | 12.6% |
Where IDEXX Laboratories ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on IDEXX Laboratories
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.